Vyome Holdings, Inc. (HIND)
| Market Cap | 17.33M |
| Revenue (ttm) | 344,591 +30.1% |
| Net Income | -9.34M |
| EPS | -13.54 |
| Shares Out | 5.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,466 |
| Open | 2.990 |
| Previous Close | 2.900 |
| Day's Range | 2.940 - 3.105 |
| 52-Week Range | 1.750 - 16.000 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 15.00 (+388.6%) |
| Earnings Date | Apr 29, 2026 |
About HIND
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Financial Performance
In 2024, Vyome Holdings's revenue was $256,944, a decrease of -38.23% compared to the previous year's $415,940. Losses were -$1.45 million, 81.0% more than in 2023.
Financial StatementsAnalyst Summary
According to one analyst, the rating for HIND stock is "Strong Buy" and the 12-month stock price target is $15.0.
News
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare co...
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results.
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study.
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
CAMBRIDGE, Mass.--(BUSINESS WIRE)--LICH LOI with Remus.
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome VT-1953 P2 results.
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In ...
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings Third Quarter 2025 Earnings Release.
Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation
“From 2019 to 2025, the biomarker landscape has seen a surge in strategic collaborations, licensing, and acquisitions, driven by the growing demand for precision medicine, companion diagnostics, and t...
Vyome Holdings Announces Results of Annual Shareholder Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Annual meeting of Vyome Holdings Inc.
Vyome Holdings Acquires MIT AI Spinout Oculo Health
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo,...
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the...
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technolog...
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced the interim results from its investigator-initiated Phase...
Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio
CAMBRIDGE, Mass. & PUNE, India--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, and Embryyo Technologies today announced the signing of an ...
Vyome Announces Strategic Review of Livechain (OTCID: LICH)
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced its Board of Directors has agreed to conduct a ...
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company targeting immuno-inflammatory and rare diseases in the US and global markets wit...
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with l...
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large marke...
Vyome Announces New Board of Directors with Deep MIT and AI Ties
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potentia...
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
IRVINE, Calif.--(BUSINESS WIRE)---- $HIND--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced ...
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Enhances and Broadens the Company's Intellectual Property Port...